AUSTIN, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Tiny Health, the first precision microbiome wellness platform built for lifelong health, today announced it has surpassed 100,000 people and 3,000 ...

Merck’s Keytruda, the category-defining CPI, reported $29.5 billion in revenue in 2024, with NSCLC representing an estimated 30% of its total sales. Keytruda is expected to approach $35 billion by ...

Targeted early-life probiotic interventions using Bifidobacterium longum subspecies infantis strains can safely restore Bifidobacterium dominance, decrease stool pH, reduce virulence factors, and ...

NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- With the New York City Employees (NYCE) PPO health plan going live January 1, EmblemHealth issued the following statement regarding its new agreement with ...

EssilorLuxottica announces it is joining forces with Fondazione Chips-IT, Italy’s research center specializing in advanced integrated-circuit design, during today’s presentation of the foundation’s ...

The strong immune response was confirmed in CHIKV-naïve children with a 94.7% seroresponse rate (full dose) at Day 360. The vaccine was well tolerated in children aged one to eleven years regardless ...

Priority Partners’ Cupboards Project was started in 2021 to address food insecurity in the communities it serves. Adding the Glen Burnie and Greenbelt locations brings the total number of ...

A French national, Tristan Imbert began his career in R&D at Sanofi Aventis in 1989. In 2000, he joined the Boston Consulting Group, advising pharmaceutical industry clients in New York and Paris, ...

Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel ...

Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis for acne in China as ASC40, and by Sagimet for metabolic dysfunction associated ...

VTP-1000 is an investigational, injectable antigen-specific tolerance immunotherapy that utilizes Barinthus Bio’s proprietary SNAP-TI platform to co-deliver multiple gluten-derived peptide antigens ...

Ajax Therapeutics, Inc ., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced that the U.S. Food and Drug ...